Previous analysis of TIMP1 expression levels using immunohistochemistry has shown significantly elevated levels in gastroenteropancreatic (Voland et al., 2008), bronchopulmonary (Blicharz-Dorniak et al., 2012), and primary skin (Massi et al., 2003) neuroendocrine tumors as well as the glandular epithelium of IBD (Jakubowska et al., 2016). Here, TIMP1 is linked to neuroendocrine neoplasm.